292 related articles for article (PubMed ID: 10420460)
1. [Low doses of recombinant erythropoietin in the treatment of renal anemia in patients on chronic hemodialysis and ambulatory peritoneal dialysis].
Lashutin SV; Nikolaev AIu; Ermolenko VM; Shutov EV; Bezruk VG; Ivashchenko MA
Ter Arkh; 1999; 71(6):61-3. PubMed ID: 10420460
[TBL] [Abstract][Full Text] [Related]
2. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous erythropoietin in the treatment of renal anaemia.
Drinovec J; Varl J
Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
[TBL] [Abstract][Full Text] [Related]
4. [Erythropoietin drugs in patients with chronic renal failure at the stage of conservative treatment. Effectiveness and side effects].
Alekseeva TB; Nikolaev AIu; Dasaeva LA
Ter Arkh; 2000; 72(6):58-60. PubMed ID: 10900653
[TBL] [Abstract][Full Text] [Related]
5. [Single weekly dose of recombinant erythropoietin in children with chronic renal insufficiency].
Guízar JM; Gutiérrez MJ; Sánchez G; Kornhauser C
Rev Invest Clin; 1996; 48(3):173-7. PubMed ID: 8966377
[TBL] [Abstract][Full Text] [Related]
6. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
7. [Influence of chronic renal failure and of its treatment on serum erythropoietin].
Remacha AF; Oliver A; Calero F; Barceló MJ; Doñate T; Ballarín JA; García-Die F
Med Clin (Barc); 1992 Jun; 99(4):125-7. PubMed ID: 1635404
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
9. [Use of erythropoietin in patients with chronic renal insufficiency and in hemodialysis].
Cuero CJ; Pérez Guardia E; de Rivera C
Rev Med Panama; 1996; 21(1-2):55-9. PubMed ID: 8966240
[TBL] [Abstract][Full Text] [Related]
10. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
Raja R; Bloom E; Johnson R
Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
[TBL] [Abstract][Full Text] [Related]
12. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
14. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
15. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
17. Epoetin omega for treatment of anemia in maintenance hemodialysis patients.
Sikole A; Spasovski G; Zafirov D; Polenakovic M
Clin Nephrol; 2002 Mar; 57(3):237-45. PubMed ID: 11924756
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
19. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
